The HPV Vaccine Acceleration Program Partners Initiative (HAPPI) Consortium, funded by the Bill & Melinda Gates Foundation combines expertise in policy, access, introduction, implementation, and evaluation and learning to accelerate uptake of HPV vaccines.
The consortium aims to increase and sustain equity, program quality, and accelerate coverage of HPV vaccination among girls and adolescents to contribute to the Gavi, the Vaccine Alliance, goal of 84M girls and adolescents vaccinated by 2025 and the global goal of 90% coverage by 2030.HAPPI partners seek to achieve this through: enabling global coordination and compilation of evidence to inform policy decisions; providing targeted country technical assistance for HPV vaccine decision-making, introduction, acceleration, and sustaining coverage in select countries; and conducting monitoring, evaluation, and learning to build on the existing evidence base. The consortium is managed by JSI together with Clinton Health Access Initiative (CHAI), the International Vaccine Access Center (IVAC) at the Johns Hopkins Bloomberg School of Public Health, Jhpiego, and PATH as partners.
We strive to build lasting relationships to produce better health outcomes for all.
